64p * metastatic breast cancer: getting the facts from peripheral blood.SalamoonMedical Oncologyal Bairouni University HospitalM.Medical Oncologyal Bairouni University HospitalAnnals of Oncology
US, said: “Approximately half of all patients with breast cancer have tumors that are HER2-low, which have previously been classified as HER2-negative and have not had effective treatment options with HER2-targeted medicines. Base...
Given the above-mentioned features of their primary breast cancer, population-based statistics and, sometimes, primary tumour gene expression tests,31 newly diagnosed patients receive a prognosis for their risk of recurrence. However, the heterogeneity of breast cancer is such that accurate predictions ...
And, certainly, social determinants of health contribute to the disparities we see. Every time we take care of a Black patient or a woman of color we know those facts, we know those statistics, and so the question is, what do we do to work toward addressing those disparities? ALLURE: ...
1Cancer Facts & Figures 2024. ACS. Available at:https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf. AccessedSeptember 2024. 2Patient education: Treatment for advanced prostate cancer (Beyon...
AstraZeneca and Daiichi Sankyo’s ENHERTU®(fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or I...
American Cancer Society – Cancer Facts and Figures 2024. Available : https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf https://www.cancer...
Ken Takeshita, Global Head, R&D, Daiichi Sankyo, said: “The results seen in the DESTINY-Breast04 trial represent a significant advance and reinforce the potential for ENHERTU to become a new standard of care for patients with previously treated...
Oncological and Oral Sciences, Section of Surgical, University of Palermo, Palermo, Italy Objective: Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the trea...
Daiichi Sankyo and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen either in the metast...